Home

Johnson & Johnson (JNJ)

177.40
+0.00 (0.00%)
NYSE · Last Trade: Sep 16th, 7:33 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
3 Dividend-Paying ETFs to Buy in September Even If the S&P 500 Sells Offfool.com
Dividend-paying growth stocks and covered call ETFs provide opportunities to generate income even in a declining stock market.
Via The Motley Fool · September 16, 2025
Big Pharma Eyes China: J&J And Roche Reportedly In Talks For Henlius’ Experimental Cancer Drugstocktwits.com
Via Stocktwits · September 15, 2025
3 Dividend Growers That Fly Under the Radarmarketbeat.com
These three companies may have what it takes to continue to build on their strong history of dividend payments even if the economy continues to sour.
Via MarketBeat · September 15, 2025
A Gathering Storm: U.S. Economy Grapples with Recessionary Headwinds
The United States economy is facing an increasingly complex and concerning confluence of risk factors, raising the specter of a looming recession. A deteriorating labor market, persistently high inflation, and the ongoing, disruptive impact of trade tariffs are interacting in ways that significantly elevate economic uncertainty for businesses, consumers, and
Via MarketMinute · September 15, 2025
Navigating the Shifting Sands: A Comprehensive Economic Outlook for 2025
As the global economy marches into 2025, it finds itself at a critical juncture, balancing the promise of moderate growth against the persistent shadows of tenacious inflation, geopolitical instability, and evolving labor market dynamics. This year is set to be defined by a complex interplay of forces that will shape
Via MarketMinute · September 15, 2025
Recession Radar: A Divergent Outlook on America's Economic Future
The U.S. economy finds itself at a crossroads, with leading financial institutions and economic forecasters presenting a varied, yet generally cautious, outlook on the probability of a recession. From machine learning algorithms to traditional yield curve models, the consensus is that while a severe downturn isn't a foregone conclusion,
Via MarketMinute · September 15, 2025
Stalling Job Market Rings Alarm Bells: August Employment Data Signals Economic Headwinds and Intensified Rate Cut Expectations
The latest U.S. employment report for August 2025 has sent a palpable chill through financial markets and economic forecasts, confirming a significant deceleration in the nation's labor market. Following a rare job contraction in June—the first monthly decline in nonfarm jobs since December 2020—the unemployment rate has
Via MarketMinute · September 15, 2025
Federal Reserve's Unexpected September Hold: A Looming Market Shock and an Estimated 8% S&P 500 Plunge
Financial markets are currently on edge, grappling with the looming possibility of a significant shock: an unexpected decision by the Federal Reserve to forgo a widely anticipated interest rate cut in September 2025. This deviation from market consensus, which largely projects a 25-basis-point reduction, could trigger a sharp negative reaction
Via MarketMinute · September 15, 2025
September's Shadow: Will the Notorious 'September Effect' Offer Bargains or Bring Bigger Bears to Wall Street?
As autumn leaves begin to fall, a familiar chill often descends upon the financial markets, not just in temperature but in investor sentiment. September has historically earned a notorious reputation among traders and analysts as the weakest month for equities, a phenomenon widely dubbed the "September Effect." This recurring statistical
Via MarketMinute · September 15, 2025
S&P 500's 22x Forward P/E: A Precarious Peak or Justified Premium?
The S&P 500's current forward price-to-earnings (P/E) ratio, hovering around 22x, has ignited a fervent debate across financial markets. This elevated valuation metric, significantly above historical averages, is prompting investors and analysts to question whether the market is perched precariously on a speculative bubble or if a new
Via MarketMinute · September 15, 2025
If You'd Invested $1,000 in Johnson & Johnson (JNJ) Stock 5 Years Ago, Here's How Much You'd Have Todayfool.com
The answer might surprise you.
Via The Motley Fool · September 15, 2025
Navigating the Storm: Diversification and Hedging Amidst Unprecedented Market Volatility
The global financial landscape is currently grappling with a potent concoction of heightened market instability, pervasive policy uncertainty, and an escalating array of geopolitical events. These formidable forces are collectively reshaping investment strategies and underscoring the critical need for robust diversification and strategic hedging within portfolios. As investors navigate these
Via MarketMinute · September 12, 2025
The Lingering Shadow: Sticky Inflation and Central Banks' Tightrope Walk in 2025
Global financial markets in 2025 are navigating a complex landscape shaped by persistently high, or "sticky," inflation and the increasingly cautious stance of major central banks regarding interest rate adjustments. Despite initial hopes for a swift return to pre-pandemic price stability, inflation, particularly in the services sector and fueled by
Via MarketMinute · September 12, 2025
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this
Via MarketMinute · September 12, 2025
Income Under Pressure: Why Covered Calls Are Capturing Investor Attention in Turbulent Markets
In an era defined by persistent market volatility and an ongoing search for reliable income streams, a historically potent, yet sometimes overlooked, options strategy is experiencing a significant resurgence: the covered call. As global financial markets navigate a landscape shaped by inflation concerns, fluctuating interest rates, and geopolitical uncertainties, investors
Via MarketMinute · September 12, 2025
The Enduring Allure of Dividends: Blue-Chip Stocks as a Bedrock for Income and Growth
In an ever-fluctuating financial landscape, where market volatility and economic uncertainties often dominate headlines, the timeless appeal of dividend-paying stocks continues to shine as a classic and dependable strategy for investors. Particularly, an investment focus on established blue-chip companies, renowned for their stability and financial fortitude, offers a compelling pathway
Via MarketMinute · September 12, 2025
Small-Cap and Value Stocks Poised for Resurgence as Federal Reserve Rate Cuts Loom
The financial markets are on the cusp of a significant "Great Rebalancing," with small-cap and value stocks emerging from a prolonged period of underperformance to challenge the dominance of mega-cap technology and growth companies. As the Federal Reserve signals an increasingly dovish stance and the anticipation of interest rate cuts
Via MarketMinute · September 12, 2025
Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 Nextbenzinga.com
Johnson & Johnson investors focus on its pharma strength, legal strategy shift, and growth in medical devices amid sector challenges.
Via Benzinga · September 12, 2025
Global Storm Brews: International Headwinds Force Fed's Hand in Pivotal Policy Decisions
The global economy is currently navigating a treacherous landscape, marked by a confluence of significant headwinds that are increasingly dictating the Federal Reserve's monetary policy path. Intensifying geopolitical tensions, a palpable resurgence of protectionist trade policies, stubbornly persistent inflationary pressures, and a general deceleration in global economic growth are the
Via MarketMinute · September 11, 2025
7 No-Brainer Robotics Stocks to Buy Right Nowfool.com
These robotics leaders are positioned to capitalize as AI transforms machines from tools into intelligent partners.
Via The Motley Fool · September 11, 2025
Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgerybenzinga.com
The FDA approved Johnson & Johnson's Inlexzo, offering a new bladder cancer treatment option with high response rates for patients, avoiding surgery.
Via Benzinga · September 10, 2025
The Specter of Stagflation: A Looming Threat to Global Markets
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high unemployment, and persistent inflation. This peculiar confluence, which defies traditional economic models, is sending ripples of concern through financial markets and
Via MarketMinute · September 10, 2025
Global Growth Hits the Brakes: A Mixed Economic Picture Emerges for 2025 and Beyond
The global economy is bracing for a significant slowdown, with leading financial institutions projecting a challenging landscape for 2025 and the years to follow. A confluence of escalating trade tensions, persistent policy uncertainty, and tighter financial conditions is converging to paint a picture of decelerated growth, raising concerns about job
Via MarketMinute · September 10, 2025
The Federal Reserve Under Siege: A Threat to Monetary Policy Independence
Concerns are escalating over the Federal Reserve's long-standing independence as political pressure intensifies, raising fundamental questions about the future of U.S. monetary policy and its implications for financial markets. Recent actions from the executive branch, including an attempted dismissal of a sitting Fed governor and the nomination of individuals
Via MarketMinute · September 10, 2025
Johnson & Johnson Kicks Off 'Powerful New Product Cycle': Analystbenzinga.com
Johnson & Johnson analyst Asad Haider says Inlexzo is currently the only intravesical iDRS to deliver cancer meds directly into the bladder.
Via Benzinga · September 10, 2025